THER-09. ONCOLYTIC ADENOVIRUS, DNX-2401, FOR NAIVE DIFFUSE INTRINSIC PONTINE GLIOMAS: A PHASE I CLINICAL TRIAL

The objective of this trial is to determine the safety, tolerability, and toxicity of DNX-2401 in newly diagnosed DIPG patients (NCT03178032) followed by radiotherapy. Secondary endpoints are overall survival at 12 months, percentage of responses and induced immune response against tumor. Tumor biop...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Iñigo-Marco, Ignacio, Gonzalez-Huarriz, Marisol, García-Moure, Marc, Tamayo, Ibon, Hervas, Sandra, Hernandez, Ruben, Buñales, Maria, DeAndrea, Carlos, Villalba, Maria, Jones, Chris, MacKay, Alan, Hulleman, Esther, Van der Lugt, Jasper, Aldave, Guillermo, Lopez-Ibor, Blanca, Patiño-Garcia, Ana, Diez-Valle, Ricardo, Fueyo, Juan, Gomez-Manzano, Candelaria, de Larraya, Jaime Gallego Perez, Tejada, Sonia, Alonso, Marta M
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2020
Konular:
Viral/Gene Therapy and other Novel Therapies
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7715674/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa222.859
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller